Avenge Bio's AVB-001 IND application receives US FDA approval for peritoneal malignancies.

M2 EQUITYBITES-August 4, 2022-Avenge Bio's AVB-001 IND application receives US FDA approval for peritoneal malignancies

(C)2022 M2 COMMUNICATIONS http://www.m2.com

Avenge Bio, Inc., a US-based biotechnology company, announced on Wednesday that it has received approval from the US Food and Drug Administration (FDA) for the Investigational New Drug (IND) application for AVB-001 in peritoneal malignancies.

AVB-001 is the first clinical application of the LOCOcyte platform, encapsulating cells designed to secrete native IL-2 in immune-activating alginate capsules. The first-in-human AVB-001 clinical trial will be an intraperitoneal administration to...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT